Peter Mesenbrink

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Machine Learning

Clinical Evaluation

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew McTeer, Douglas Applegate, Peter Mesenbrink, Vlad Ratziu, Jörn M Schattenberg, Elisabetta Bugianesi, Andreas Geier, Manuel Romero Gomez, Jean-Francois Dufour, Mattias Ekstedt, Sven M Francque, Hannele Yki-Jarvinen, Michael Allison, Luca Vittorio Valenti, Luca Miele, Michael Pavlides, Jeremy Cobbold, Georgios Papatheodoridis, Adriaan G Holleboom, Dina Tiniakos, Clifford Brass, Quentin Mark Anstee, Paolo Missier, null null
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PloS one 19 (2) (2024)
Matthew McTeer, Douglas Applegate, Peter Mesenbrink, Vlad Ratziu, Jörn M Schattenberg, Elisabetta Bugianesi, Andreas Geier, Manuel Romero Gomez, Jean-Francois Dufour, Mattias Ekstedt, Sven M Francque, Hannele Yki-Jarvinen, Michael Allison, Luca Vittorio Valenti, Luca Miele, Michael Pavlides, Jeremy Cobbold, Georgios Papatheodoridis, Adriaan G Holleboom, Dina Tiniakos, Clifford Brass, Quentin Mark Anstee, Paolo Missier, null null
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PloS one 19 (2) (2024)
Matthew McTeer, Douglas Applegate, Peter Mesenbrink, Vlad Ratziu, Jörn M Schattenberg, Elisabetta Bugianesi, Andreas Geier, Manuel Romero Gomez, Jean-Francois Dufour, Mattias Ekstedt, Sven M Francque, Hannele Yki-Jarvinen, Michael Allison, Luca Vittorio Valenti, Luca Miele, Michael Pavlides, Jeremy Cobbold, Georgios Papatheodoridis, Adriaan G Holleboom, Dina Tiniakos, Clifford Brass, Quentin Mark Anstee, Paolo Missier, null null
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PloS one 19 (2) (2024)
Madhavi Gidh-Jain, Tom Parke, Franz König, Cecile Spiertz, Peter Mesenbrink, null null
Developing generic templates to shape the future for conducting integrated research platform trials. Trials 25 (1) (2024)
Madhavi Gidh-Jain, Tom Parke, Franz König, Cecile Spiertz, Peter Mesenbrink, null null
Developing generic templates to shape the future for conducting integrated research platform trials. Trials 25 (1) (2024)
Madhavi Gidh-Jain, Tom Parke, Franz König, Cecile Spiertz, Peter Mesenbrink, null null
Developing generic templates to shape the future for conducting integrated research platform trials. Trials 25 (1) (2024)
Madhavi Gidh-Jain, Tom Parke, Franz König, Cecile Spiertz, Peter Mesenbrink, null null
Developing generic templates to shape the future for conducting integrated research platform trials. Trials 25 (1) (2024)
Quynh Lan Nguyen, Katharina Hees, Sabina Hernandez Penna, Franz Koenig, Martin Posch, Marta Bofill Roig, Elias Laurin Meyer, Michaela Maria Freitag, Tom Parke, Maximilian Otte, Hans Peter Dauben, Tobias Mielke, Cecile Spiertz, Peter Mesenbrink, Madhavi Gidh-Jain, Suzanne Pierre, Salvatore Morello, Benjamin Hofner
Regulatory Issues of Platform Trials: Learnings from EU-PEARL. Clinical pharmacology and therapeutics 116 (1) (2024)
Quynh Lan Nguyen, Katharina Hees, Sabina Hernandez Penna, Franz Koenig, Martin Posch, Marta Bofill Roig, Elias Laurin Meyer, Michaela Maria Freitag, Tom Parke, Maximilian Otte, Hans Peter Dauben, Tobias Mielke, Cecile Spiertz, Peter Mesenbrink, Madhavi Gidh-Jain, Suzanne Pierre, Salvatore Morello, Benjamin Hofner
Regulatory Issues of Platform Trials: Learnings from EU-PEARL. Clinical pharmacology and therapeutics (2024)
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf, Ekkehard Glimm, Yuhan Li, Franz Koenig, null null
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials. Pharmaceutical statistics 21 (3) (2022)